Hisamitsu Pharmaceutical Co (FSE:4530) Long-Term Debt: 円1,431 Mil (As of Nov. 2025)


FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co Long-Term Debt?

Hisamitsu Pharmaceutical Co FSE:4530 89 Long-Term Debt is 円1,431 Mil as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07.

Hisamitsu Pharmaceutical Co's Long-Term Debt for the quarter that ended in Nov. 2025 was 円1,431 Mil.

Hisamitsu Pharmaceutical Co's quarterly Long-Term Debt declined from May. 2025 (円1,683 Mil) to Aug. 2025 (円1,431 Mil) but then stayed the same from Aug. 2025 (円1,431 Mil) to Nov. 2025 (円1,431 Mil).

Hisamitsu Pharmaceutical Co's annual Long-Term Debt increased from Feb. 2024 (円76 Mil) to Feb. 2025 (円1,694 Mil) but then declined from Feb. 2025 (円1,694 Mil) to Feb. 2026 (円0 Mil).

Hisamitsu Pharmaceutical Co  (FSE:4530) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Hisamitsu Pharmaceutical Co Long-Term Debt Related Terms

Hisamitsu Pharmaceutical Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Long-Term Debt Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 219.00 147.00 76.00 1,694.00 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,694.00 1,683.00 1,431.00 1,431.00 0.00
FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円1,431 Mil mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a Long-Term Debt of 円1,431 Mil as of Nov. 2025.
Is Hisamitsu Pharmaceutical Co's Long-Term Debt too high?
Hisamitsu Pharmaceutical Co's current Long-Term Debt is 円1,431 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Long-Term Debt compare to ESPR and AMPH?
Hisamitsu Pharmaceutical Co's Long-Term Debt of 円1,431 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Hisamitsu Pharmaceutical Co's current Long-Term Debt is 円1,431 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Long-Term Debt of 円1,431 Mil. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Long-Term Debt is 円1,431 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Long-Term Debt is 円1,431 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • Long-Term Debt: 円1,431 Mil
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value